Application of a pyrimidone derivative in the preparation of drugs for delaying aging and prolonging life
By using the pyrimidinone derivative 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydro)-pyrimidinone, the application gap of pyrimidinone derivatives in delaying aging and prolonging lifespan was filled, and the effect of significantly prolonging the lifespan of Caenorhabditis elegans was achieved.
Patent Information
- Application Number
- CN202410686893.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-05-30
AI Technical Summary
There are no literature reports on the application of pyrimidinone derivatives in delaying aging and prolonging lifespan in the existing technology.
A pharmaceutical composition was prepared using the pyrimidinone derivative 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydro)-pyrimidinone as the active ingredient, and its anti-aging and life-extending effects on Caenorhabditis elegans were verified through experiments.
Experimental results show that this pyrimidinone derivative can significantly prolong the lifespan of Caenorhabditis elegans, exhibits strong anti-aging activity, and has the potential to be used in drugs for delaying aging and prolonging life.
Smart Images

Figure CN118512456B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and particularly relates to the application of a pyrimidone derivative in the preparation of drugs for delaying aging and prolonging life. Background Art
[0002] With the extension of human life span and the arrival of an aging society, aging has become a social and scientific issue that has attracted much attention. In the biomedical field, the study of aging has become a hot topic, and scientists are constantly exploring ways to delay aging and increase healthy life expectancy in order to meet the challenges brought by an aging society.
[0003] With the in-depth study of the aging mechanism, scientists continue to explore intervention methods for aging, hoping to delay the aging process and increase healthy life expectancy. The research and development of anti-aging drugs has become a field of great concern, and various potential anti-aging drugs continue to emerge.
[0004] As a simple and easy-to-operate experimental model, C. elegans has a short life cycle and a clear genetic background, making it an ideal model for aging research. By screening and studying anti-aging drugs in C. elegans, scientists can quickly evaluate the anti-aging effects of drugs, reveal the mechanism of action of drugs, and provide important references for further drug development.
[0005] Aging is a complex biological process that is affected by many factors. The development of anti-aging drugs has become a field of great concern. By using nematodes as a model organism for drug screening and research, it is expected to provide new solutions for delaying aging and increasing healthy lifespan.
[0006] So far, there has been no literature report on the ability of pyrimidinone derivatives, specifically 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydrogen)-pyrimidinone, to delay aging and prolong life. Summary of the invention
[0007] In view of the technical problems existing in the background technology, the purpose of the present invention is to provide an application of a pyrimidone derivative in the preparation of drugs for delaying aging and prolonging life.
[0008] In order to achieve the above object, the present invention adopts the following technical solution:
[0009] The first aspect of the present invention provides an application of a pyrimidone derivative in the preparation of a drug for delaying aging and prolonging life, wherein the pyrimidone derivative is specifically 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydrogen)-pyrimidone, with a molecular formula of C 16 H 17 F 3 N2 O 3 , molecular weight is 342.31, structural formula is shown in formula (Ⅰ):
[0010]
[0011] Preferably, the drug is a pharmaceutical composition comprising the above-mentioned pyrimidone derivative as an active ingredient and pharmaceutically acceptable excipients.
[0012] The present invention has the following beneficial effects:
[0013] The present invention investigates the effect of a pyrimidinone derivative, specifically 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3H)-pyrimidinone, on the lifespan of transgenic Caenorhabditis elegans. The experimental results show that 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3H)-pyrimidinone has strong anti-aging activity, can effectively prolong the lifespan of Caenorhabditis elegans, and is expected to be used in the preparation of various anti-aging and life-extending drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0015] Figure 1 The structural formula is 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydrogen)-pyrimidinone;
[0016] Figure 2 This is a graph showing the experimental results of the effect of 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydrogen)-pyrimidinone on the life span of Caenorhabditis elegans;
[0017] Figure 3 This is a graph showing the experimental results of the effect of 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydrogen)-pyrimidinone on the transcription levels of aging-related genes gcs-1 and gst-4. DETAILED DESCRIPTION
[0018] In the following description, for the purpose of illustration rather than limitation, specific details such as specific system structures and technologies are provided to provide a thorough understanding of the embodiments of the present invention. However, it should be clear to those skilled in the art that the present invention may also be implemented in other embodiments without these specific details.
[0019] Example 1
[0020] This example uses the Caenorhabditis elegans model as a model for evaluating the anti-aging and life-extending activities of 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydrogen)-pyrimidinone (commercially available). The detection steps are:
[0021] (1) Solution preparation
[0022] 3-[2-Hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydrogen)-pyrimidinone was dissolved in DMSO to prepare a sample stock solution with a concentration of 10 mM, and then diluted to a concentration of 100 μM with NGM culture medium.
[0023] (2) Cultivation of Caenorhabditis elegans
[0024] Under laboratory conditions, Caenorhabditis elegans feeds on Escherichia coli OP50. A single colony of E. coli is inoculated into LB liquid culture medium and grown at 37°C at 200 rpm for 16 hours. Then 100 μL of the bacterial liquid is added to a 35 mm solid nematode growth medium (NGM) and incubated at room temperature overnight to give it a certain thickness. The Caenorhabditis elegans is then picked onto the NGM and cultured in a 20°C biochemical incubator.
[0025] (3) Lifespan test of Caenorhabditis elegans
[0026] Caenorhabditis elegans were cultured at 20°C from the embryonic stage to the fourth larval stage (L4), and then transferred to NGM medium supplemented with 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydrogen)-pyrimidinone (final concentration 100 μM) (denoted as compound 1 group). The control group was supplemented with an equal volume of DMSO, and the survival test was performed in a 25°C biochemical incubator. The number of nematodes that survived, died, or were lost was counted from the first day of the adult stage, and the odd-numbered days were counted until all died. Nematodes that did not respond to the touch of platinum wire were considered dead, and deaths caused by reasons other than aging were considered lost. At least 60 nematodes were synchronized for each sample, and the same trend was obtained by repeating three times. The survival curve and significant difference were drawn using Prism 5 software (Graphpad Software, Inc., San Diego, CA, USA). In summary, the effect of the compound on extending the lifespan of Caenorhabditis elegans can be calculated, and the experimental results are shown in Figure 2 .
[0027] Depend on Figure 2 The experimental results show that the median survival time of the negative control group was 13.55 days, and the life span of the Caenorhabditis elegans treated with the compound group sample (100 μM) was extended to 16.9 days, an increase of 24.7% compared with the control group, which is a very significant difference ( **** P<0.0001). This phenomenon indicates that 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydrogen)-pyrimidinone can prolong the lifespan of Caenorhabditis elegans and has anti-aging activity, and it is expected to be used in the preparation of various anti-aging and life-extending drugs.
[0028] Example 2
[0029] Real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) was used to detect the transcription levels of aging-related genes gcs-1 and gst-4. The specific detection steps are as follows:
[0030] (1) Solution preparation
[0031] 3-[2-Hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydrogen)-pyrimidinone was dissolved in DMSO to prepare a sample stock solution with a concentration of 10 mM, and then diluted to a concentration of 100 μM with NGM culture medium.
[0032] (2) Cultivation of Caenorhabditis elegans
[0033] Under laboratory conditions, Caenorhabditis elegans feeds on Escherichia coli OP50. A single colony of E. coli is inoculated into LB liquid culture medium and grown at 37°C at 200 rpm for 16 hours. Then 100 μL of the bacterial liquid is added to a 35 mm solid nematode growth medium (NGM) and incubated at room temperature overnight to give it a certain thickness. The Caenorhabditis elegans is then picked onto the NGM and cultured in a 20°C biochemical incubator.
[0034] (3) RT-qPCR detection of gcs-1 and gst-4 transcription levels
[0035] To detect the transcription level of genes in the model organism Caenorhabditis elegans, 40 adult first antenna worms treated with drugs (referred to as compound 1 treatment group) were collected, placed in 100 μl Trizol solution, and immediately frozen at -80°C for 30 minutes. Total RNA was extracted using an RNA extraction kit. cDNA was synthesized using a reverse transcription kit and detected using a Roche real-time PCR instrument. 2 -ΔΔCT The algorithm was used to calculate the relative gene expression level with actin as the internal reference. Figure 3 .
[0036] Figure 3 The results showed that compared with the control treatment, the compound 1 treatment group showed significantly increased gcs-1 and gst-4 transcription levels. Both are direct regulatory target genes of SKN-1 / Nrf-2. The RT-qPCR results indicate that compound 1 treatment may mediate lifespan extension by activating the body's SKN-1 / Nrf-2 transcription factors.
[0037] The present invention is not limited to the above-mentioned specific implementation modes. Various changes made by ordinary technicians in this field based on the above-mentioned concepts without creative work are all within the protection scope of the present invention.
Claims
1. Use of a pyrimidone derivative in the preparation of a drug for delaying aging and prolonging life, wherein the pyrimidone derivative is specifically 3-[2-hydroxy-3-[3-(trifluoromethyl)phenoxy]propyl]-5,6-dimethyl-4(3-hydrogen)-pyrimidone, with a molecular formula of C 16 H 17 F 3 N 2 O 3 , molecular weight is 342.31, structural formula is shown in formula (Ⅰ):
2. Use of the pyrimidone derivative according to claim 1 in the preparation of drugs for delaying aging and prolonging life, Features: The medicine is a pharmaceutical composition comprising the pyrimidone derivative according to claim 1 as an active ingredient and pharmaceutically acceptable excipients.
